The Xolair® Pregnancy Registry: An Observational Study of the Use and Safety of Xolair® (Omalizumab) During Pregnancy
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 28 Dec 2017
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Acronyms EXPECT
- Sponsors Genentech
- 03 Oct 2017 Planned End Date changed from 1 Aug 2017 to 5 Jan 2018.
- 03 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 12 Dec 2017.
- 26 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.